Novartis posts daNIS-3 phase 2 results; registers Phase 3 PINNACLE-MI cardiac trial
Novartis closed out oncology results, a new Phase 3 cardiovascular study and two completed Japanese drug-use surveys this week.
Novartis had a busy week across oncology, cardiology and post-marketing surveillance registry updates.
- Novartis terminated the Phase 2 "daNIS-3" platform study (NCT04952753) testing NIS793 combinations for second-line metastatic colorectal cancer.
- Novartis registered a Phase 3 trial called "PINNACLE-MI" (NCT07938411) testing pacibekitug against placebo in patients after a myocardial infarction. The study aims to show superiority of pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events, a composite of coronary heart disease death, non-fatal myocardial infarction, and urgent coronary revascularization, in post-MI patients at high cardiovascular risk on standard secondary prevention therapy.1
- A Japanese post-marketing surveillance study of Fabhalta capsules in paroxysmal nocturnal hemoglobinuria (NCT06606314) was completed. The multicenter, single-arm, non-interventional study used a central registration and all-case surveillance system, with an observation period of 48 weeks after the start of Fabhalta treatment.2
- A Japanese drug-use survey of Leqvio (inclisiran) in familial hypercholesterolaemia or hypercholesterolaemia (NCT06275724) was completed. The objective was to evaluate the long-term safety of Leqvio in post-marketing clinical practice.3
Fact check notes
- Sentence removed
Administration of NIS793 and tislelizumab was halted on July 31, 2023, and the action was classified as an Urgent Safety Measure on August 3, 2023, due to an unfavorable benefit/risk profile observed in participants with metastatic colorectal cancer.
copied source wording - Sentence removed
The trial had enrolled 202 participants, and results were first posted on 2026-11-16.
a figure with no citation - Sentence removed
The trial is not yet recruiting, with an estimated enrollment of 10,000 participants and an estimated start date of 2026-11-30.
a figure with no citation - Sentence removed
The study enrolled 132 participants across 90 Japanese sites.
a figure with no citation - Sentence removed
The study enrolled 585 participants across 107 sites in Japan, with a planned 24-month observation period.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.